TY - JOUR
T1 - Recent developments in liposomal drug delivery systems for the treatment of retinal diseases
AU - Urquhart, Andrew J.
AU - Eriksen, Anne Zebitz
PY - 2019
Y1 - 2019
N2 - Diseases of the retina cause vision loss and blindness, which have a profound impact on an individual's quality of life. The number of therapies available to treat retinal diseases is limited. Nanoparticle (NP)-based medicines represent one strategy to expand both the number of available therapies and the range of retinal diseases treated. Liposomes, phospholipid vesicles that frequently contain cholesterol and/or modified surface chemistries, have already had minor success in retinal disease treatment and hold significant promise. Here, we provide a snapshot of recent research developments in liposomal drug delivery systems for retinal diseases and discuss the challenges associated with liposomal systems in the context of recent developments.
AB - Diseases of the retina cause vision loss and blindness, which have a profound impact on an individual's quality of life. The number of therapies available to treat retinal diseases is limited. Nanoparticle (NP)-based medicines represent one strategy to expand both the number of available therapies and the range of retinal diseases treated. Liposomes, phospholipid vesicles that frequently contain cholesterol and/or modified surface chemistries, have already had minor success in retinal disease treatment and hold significant promise. Here, we provide a snapshot of recent research developments in liposomal drug delivery systems for retinal diseases and discuss the challenges associated with liposomal systems in the context of recent developments.
U2 - 10.1016/j.drudis.2019.04.004
DO - 10.1016/j.drudis.2019.04.004
M3 - Journal article
C2 - 30958994
SN - 1359-6446
VL - 24
SP - 1660
EP - 1668
JO - Drug Discovery Today
JF - Drug Discovery Today
IS - 8
ER -